Your session is about to expire
← Back to Search
Ladarixin + Sotorasib for Advanced Non-Small Cell Lung Cancer
Study Summary
This trial studies a new drug combo to treat advanced lung cancer with a certain genetic mutation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been treated with KRAS inhibitors before.I am 18 years old or older.My brain or spinal cancer has been stable for at least 7 days, and I haven't taken steroids in the last 7 days.I have had lung conditions that needed steroid treatment.I haven't taken any acid-reducing medicines in the last 3 days or 5 half-lives before starting ladarixin.You are allergic to the main ingredient or other ingredients in the study drug, or to non-steroidal anti-inflammatory drugs.I haven't taken any medications known to cause heart rhythm problems in the last 2 weeks.I haven't had major surgery or trauma in the last 28 days and don't expect to need surgery until my treatment ends.I am fully active or can carry out light work.I have heart problems that affect my daily activities.I am not taking medications that are sensitive to changes in how they are broken down by my body.I haven't taken any cancer drugs or experimental drugs within the last month.I haven't taken any strong medication that affects liver enzymes in the last 14 days.I have not had radiation therapy in the week before starting ladarixin.I have a severe autoimmune disease or need long-term steroids.I started treatments like erythropoietin or G-CSF less than 2 weeks before beginning the study drug.My lung cancer cannot be cured with surgery or radiation.My cancer progressed after treatment with anti-PD(L)-1, with or without chemo.I have side effects from previous treatments that are not severe.You have tested positive for HIV antibodies before starting treatment.I have had a bone marrow or organ transplant from another person.I haven't taken any strong herbal drugs or supplements that affect liver enzymes in the last 14 days.I do not have an active infection needing treatment or have completed a 7-day break after antibiotics.My lung cancer diagnosis has been confirmed by a lab test.I have had a different type of cancer within the last year, not including certain exceptions.I have not had any blood cancer, except stable CLL, in the last year.I have had pericarditis or fluid around my heart in the last 6 months.I have had serious eye inflammation or related conditions in the last 6 months.I have not received a live vaccine within 30 days before starting the study medication.I have not had a blood or platelet transfusion in the last week.I have at least one tumor that can be measured by medical imaging.I can swallow and keep down pills.My tumor has the KRASG12C mutation.I will follow the study's birth control requirements.I have had a blockage in my bile ducts due to cancer within the last 6 months, but I have a working biliary stent.You have a neuromuscular disorder that causes high levels of creatine kinase (CK) in your body.Your blood test results at the screening need to meet certain standards for white blood cells, platelets, hemoglobin, albumin, lymphocytes, bilirubin, liver enzymes, blood clotting, and kidney function.I have an active hepatitis B or C infection.I am not allergic to ladarixin, sotorasib, or their ingredients.
- Group 1: Advanced NSCLC Patients
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any limitations on who is eligible to participate in this research?
"The requirements for this medical trial are: non-small cell lung cancer, ages between 18 and 100 years old. At the moment, 12 participants have been enrolled in the study."
Does the study allow those aged 40 and greater to participate?
"Participants in this trial should be between the ages of 18 and 100. For those under 18, there are 42 studies available while 1913 have been earmarked for patients above 65 years old."
What risks do individuals with advanced non-small cell lung cancer face?
"The safety of Advanced NSCLC Patients has been rated a 1 due to the Phase 1 status of this trial, demonstrating there is limited clinical evidence supporting its efficacy and security."
Is this experiment presently recruiting participants?
"As per clinicaltrials.gov, this particular medical trial is no longer recruiting patients. Originally posted on April 1st 2023 and most recently updated on the 4th of April, there are 1921 other trials currently accepting patient applications as well."
Share this study with friends
Copy Link
Messenger